We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current KNTPF market cap is 81.62M. The company's latest EPS is CNY -2.1327 and P/E is -0.08.
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Total Revenue | 698k | 0 | 0 | 34.23M | 0 |
| Operating Income | -109.61M | -230.15M | -399.74M | -834.4M | -969.39M |
| Net Income | -108.48M | -232.58M | -508.3M | -842.1M | -954.37M |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Total Assets | 423.6M | 553.38M | 1.85B | 2.07B | 2.06B |
| Total Liabilities | 171.92M | 183.71M | 343.54M | 412.83M | 559.95M |
| Total Equity | 251.68M | 369.66M | 1.51B | 1.66B | 1.5B |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Operating | -114.87M | -228.04M | -380.88M | -1.05B | -961.26M |
| Investing | -64.75M | -7.01M | -439.73M | 92.01M | 67.2M |
| Financing | 303.94M | 295.85M | 1.78B | 857.42M | 815.75M |
| Market Cap | 81.62M |
| Price to Earnings Ratio | -0.08 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 0.09 |
| Price to Book Ratio | 0.05 |
| Dividend Yield | - |
| Shares Outstanding | 447.5M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 1.48k |
| 52 Week Change | -61.33% |
| 52 Week High | 0.5529 |
| 52 Week Low | 0.10 |
| Spread (Intraday) | 0.18 (77.85%) |
| Company Name | Kintor Pharmaceutical Ltd (PK) |
| Address |
cricket square grand cayman KY1-1111 |
| Website | https://www.kintor.com.cn |
| Industry | coml physical, biologcl resh (8731) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
